Spectral AI Receives FDA De Novo Classification for DeepView System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- FDA Milestone: Spectral AI's DeepView System has received De Novo classification from the FDA, marking a significant advancement in the medical diagnostics field and is expected to accelerate the company's commercial distribution activities in the U.S., thereby enhancing its competitiveness in the trauma care market.
- Technological Innovation: The DeepView System combines multispectral imaging with a proprietary AI algorithm, enabling image acquisition in 0.2 seconds and processing within 20 to 25 seconds, providing clinicians with rapid, data-driven assessments of wound healing potential, significantly improving treatment decision efficiency.
- Market Potential: Designed to redefine the standard of care in burn treatment, the system is anticipated to deliver value across the healthcare ecosystem by improving patient outcomes and reducing costs, further solidifying the company's leadership position in the medical technology sector.
- Strategic Support: The project is partially funded by the U.S. Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA), highlighting government support for innovative medical technologies, which may provide a strong backing for Spectral AI's future expansion and development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDAI
Wall Street analysts forecast MDAI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.310
Low
3.00
Averages
4.50
High
6.00
Current: 2.310
Low
3.00
Averages
4.50
High
6.00
About MDAI
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Spectral AI Shares Drop 12% After FDA De Novo Classification
- Stock Decline: Shares of Spectral AI, Inc. fell approximately 12% in Tuesday morning trading, currently priced at $2.34, down 12.72% from the previous close of $2.68, indicating a negative market reaction to the news.
- FDA Approval: The company announced that its DeepView System received De Novo Classification from the U.S. Food and Drug Administration, allowing it to be used in burn care across various settings, paving the way for future commercial distribution activities.
- Historical Trading Range: Over the past year, Spectral AI's stock has fluctuated between $1.18 and $3.21, with the current price nearing the year's low, reflecting market concerns about the product's prospects.
- Commercial Activity Launch: With the De Novo Classification, Spectral AI is authorized to commence commercial distribution activities in the U.S., a significant development that, despite its importance, has not been positively reflected in market reactions.
See More
Spectral AI Receives FDA De Novo Classification for DeepView System
- FDA Milestone: Spectral AI's DeepView System has received De Novo classification from the FDA, marking a significant advancement in the medical diagnostics field and is expected to accelerate the company's commercial distribution activities in the U.S., thereby enhancing its competitiveness in the trauma care market.
- Technological Innovation: The DeepView System combines multispectral imaging with a proprietary AI algorithm, enabling image acquisition in 0.2 seconds and processing within 20 to 25 seconds, providing clinicians with rapid, data-driven assessments of wound healing potential, significantly improving treatment decision efficiency.
- Market Potential: Designed to redefine the standard of care in burn treatment, the system is anticipated to deliver value across the healthcare ecosystem by improving patient outcomes and reducing costs, further solidifying the company's leadership position in the medical technology sector.
- Strategic Support: The project is partially funded by the U.S. Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA), highlighting government support for innovative medical technologies, which may provide a strong backing for Spectral AI's future expansion and development.
See More
MindBio Leverages AI Voice Analysis for Impairment Detection
- Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and potentially enhancing public safety and health response capabilities.
- Market Potential: The company targets a market of approximately $47 billion in workplace safety and substance testing, aiming to drive industry efficiency and compliance through the application of non-invasive detection technologies to meet growing market demands.
- Scientific Basis: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of impairment signatures from various substances, providing a more comprehensive assessment than traditional single-substance tests, which holds significant clinical and societal implications.
- Industry Impact: By facilitating real-time impairment detection, MindBio's technology could reduce traffic and workplace accidents, enhancing overall societal safety, aligning with the global urgent need for rapid, scalable detection solutions.
See More
MindBio Leverages AI Voice Analysis for Impairment Detection
- Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and is expected to greatly enhance public and workplace safety.
- Market Potential: The company is targeting a market of approximately $47 billion in workplace safety and substance testing, with growing demand for efficient and scalable detection solutions, positioning MindBio's technology for widespread application across various industries.
- Scientific Foundation: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of intoxication states and providing a more comprehensive assessment compared to traditional single-substance tests, with high detection accuracy.
- Social Impact: By reducing traffic accidents and workplace incidents caused by intoxication, MindBio's non-invasive detection methods have the potential to improve public health globally and lower the societal costs associated with substance use.
See More
Spectral AI Announces 2026 Annual Stockholders Meeting
- Meeting Announcement: Spectral AI will hold its 2026 Annual Stockholders Meeting on May 29, 2026, at 9:30 a.m. CDT, with voting rights limited to stockholders of record as of April 1, 2026, ensuring shareholder engagement and decision-making authority.
- Voting Options: Shareholders can attend in person at the corporate headquarters or participate virtually by registering in advance, providing flexible participation options aimed at increasing voter turnout and engagement.
- Disclosure of Information: Important details regarding the Annual Meeting and the matters to be considered have been disclosed in the Definitive Proxy Statement filed with the SEC on April 16, 2026, ensuring shareholders are well-informed about the meeting's agenda.
- Company Overview: Spectral AI focuses on medical diagnostics, aiming to enhance treatment decisions in wound care through its DeepView System, which seeks to provide rapid and accurate treatment insights to improve patient outcomes and reduce healthcare costs.
See More
Spectral AI to Showcase DeepView System at American Burn Association Annual Meeting
- Event Participation: Spectral AI will showcase its DeepView® System at the American Burn Association Annual Meeting from April 14-17, 2026, in Orlando, Florida, attracting over 2,200 clinicians and researchers, which will enhance the company's influence in the burn care industry.
- Product Demonstration: The DeepView System combines multispectral imaging with a proprietary AI algorithm to rapidly assess the healing potential of burn wounds, enabling clinicians to make faster treatment decisions, which is expected to significantly improve patient outcomes and reduce healthcare costs.
- FDA Application Progress: Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the FDA in June 2025, and if approved, it will further accelerate the product's market entry and strengthen the company's competitive position in medical diagnostics.
- Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech Companies of 2025, highlighting its leadership in medical technology innovation and is expected to attract more investor interest in its future growth potential.
See More
Spectral AI Shares Drop 12% After FDA De Novo Classification
- Stock Decline: Shares of Spectral AI, Inc. fell approximately 12% in Tuesday morning trading, currently priced at $2.34, down 12.72% from the previous close of $2.68, indicating a negative market reaction to the news.
- FDA Approval: The company announced that its DeepView System received De Novo Classification from the U.S. Food and Drug Administration, allowing it to be used in burn care across various settings, paving the way for future commercial distribution activities.
- Historical Trading Range: Over the past year, Spectral AI's stock has fluctuated between $1.18 and $3.21, with the current price nearing the year's low, reflecting market concerns about the product's prospects.
- Commercial Activity Launch: With the De Novo Classification, Spectral AI is authorized to commence commercial distribution activities in the U.S., a significant development that, despite its importance, has not been positively reflected in market reactions.
See More
Spectral AI Receives FDA De Novo Classification for DeepView System
- FDA Milestone: Spectral AI's DeepView System has received De Novo classification from the FDA, marking a significant advancement in the medical diagnostics field and is expected to accelerate the company's commercial distribution activities in the U.S., thereby enhancing its competitiveness in the trauma care market.
- Technological Innovation: The DeepView System combines multispectral imaging with a proprietary AI algorithm, enabling image acquisition in 0.2 seconds and processing within 20 to 25 seconds, providing clinicians with rapid, data-driven assessments of wound healing potential, significantly improving treatment decision efficiency.
- Market Potential: Designed to redefine the standard of care in burn treatment, the system is anticipated to deliver value across the healthcare ecosystem by improving patient outcomes and reducing costs, further solidifying the company's leadership position in the medical technology sector.
- Strategic Support: The project is partially funded by the U.S. Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA), highlighting government support for innovative medical technologies, which may provide a strong backing for Spectral AI's future expansion and development.
See More
MindBio Leverages AI Voice Analysis for Impairment Detection
- Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and potentially enhancing public safety and health response capabilities.
- Market Potential: The company targets a market of approximately $47 billion in workplace safety and substance testing, aiming to drive industry efficiency and compliance through the application of non-invasive detection technologies to meet growing market demands.
- Scientific Basis: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of impairment signatures from various substances, providing a more comprehensive assessment than traditional single-substance tests, which holds significant clinical and societal implications.
- Industry Impact: By facilitating real-time impairment detection, MindBio's technology could reduce traffic and workplace accidents, enhancing overall societal safety, aligning with the global urgent need for rapid, scalable detection solutions.
See More
MindBio Leverages AI Voice Analysis for Impairment Detection
- Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and is expected to greatly enhance public and workplace safety.
- Market Potential: The company is targeting a market of approximately $47 billion in workplace safety and substance testing, with growing demand for efficient and scalable detection solutions, positioning MindBio's technology for widespread application across various industries.
- Scientific Foundation: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of intoxication states and providing a more comprehensive assessment compared to traditional single-substance tests, with high detection accuracy.
- Social Impact: By reducing traffic accidents and workplace incidents caused by intoxication, MindBio's non-invasive detection methods have the potential to improve public health globally and lower the societal costs associated with substance use.
See More
Spectral AI Announces 2026 Annual Stockholders Meeting
- Meeting Announcement: Spectral AI will hold its 2026 Annual Stockholders Meeting on May 29, 2026, at 9:30 a.m. CDT, with voting rights limited to stockholders of record as of April 1, 2026, ensuring shareholder engagement and decision-making authority.
- Voting Options: Shareholders can attend in person at the corporate headquarters or participate virtually by registering in advance, providing flexible participation options aimed at increasing voter turnout and engagement.
- Disclosure of Information: Important details regarding the Annual Meeting and the matters to be considered have been disclosed in the Definitive Proxy Statement filed with the SEC on April 16, 2026, ensuring shareholders are well-informed about the meeting's agenda.
- Company Overview: Spectral AI focuses on medical diagnostics, aiming to enhance treatment decisions in wound care through its DeepView System, which seeks to provide rapid and accurate treatment insights to improve patient outcomes and reduce healthcare costs.
See More
Spectral AI to Showcase DeepView System at American Burn Association Annual Meeting
- Event Participation: Spectral AI will showcase its DeepView® System at the American Burn Association Annual Meeting from April 14-17, 2026, in Orlando, Florida, attracting over 2,200 clinicians and researchers, which will enhance the company's influence in the burn care industry.
- Product Demonstration: The DeepView System combines multispectral imaging with a proprietary AI algorithm to rapidly assess the healing potential of burn wounds, enabling clinicians to make faster treatment decisions, which is expected to significantly improve patient outcomes and reduce healthcare costs.
- FDA Application Progress: Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the FDA in June 2025, and if approved, it will further accelerate the product's market entry and strengthen the company's competitive position in medical diagnostics.
- Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech Companies of 2025, highlighting its leadership in medical technology innovation and is expected to attract more investor interest in its future growth potential.
See More
